AIT Worldwide Logistics expands presence in Malaysia with new facilities in Johor Bahru, Kuala Lumpur
AIT Worldwide Logistics, a global supply chain solutions leader, today announced the opening of two new offices in Malaysia—one in Johor Bahru and another in Kuala Lumpur. These strategic additions are part of the company’s continuing organic global expansion to better serve its customers, particularly in the technology and manufacturing sectors, throughout the Asia-Pacific region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241112454642/en/
AIT Worldwide Logistics' most recent organic expansion in the Asia-Pacific region features two new offices in Malaysia. (Photo: Business Wire)
The Johor Bahru office is positioned in one of Malaysia’s key economic states, which is poised for exceptional growth. The office’s location offers unparalleled access to Singapore, fast-growing manufacturing markets, and a technology hub where leading companies have recently established operations. Known as one of the most promising global AI-related manufacturing sites, Johor Bahru is primed to play a significant role in the global supply chain.
“Our new Johor Bahru office will be instrumental in supporting AIT’s expansion strategy across Southeast Asia,” said AIT’s Chief Business Officer, Greg Weigel. “By establishing a presence here, we aim to foster deeper connections with customers, especially in the technology and manufacturing sectors, while delivering world-class logistics solutions that meet growing demands.”
Meanwhile, the Kuala Lumpur office is located in nearby Cyberjaya, which is home to AIT customers from a diverse range of businesses, including companies in the industrial, technology, healthcare, food, consumer retail, and energy sectors. And with many Tier 2 suppliers based in the region, AIT anticipates strong air cargo demand, particularly in the technology industry.
“With these new locations in Malaysia, we are excited to extend even greater flexibility and efficiency to our customers,” said AIT’s Senior Vice President, Asia Pacific, Wilson Lee. “These offices reflect our organizational commitment to providing innovative logistics solutions tailored to our customers’ business needs.”
Both new AIT offices provide a full suite of transportation management services, including comprehensive air, sea, and ground freight solutions, warehouse management, third-party logistics, transborder, white glove delivery, project cargo, and in-house customs clearance.
Joining more than 150 AIT facilities around the globe, the new offices are also connected to critical transport infrastructure, including proximity to major ports, airports, highways, and public transit systems, ensuring seamless logistics operations across the region.
Additionally, as part of AIT’s continued investment in Asia, the company is relocating its Taipei office to a larger facility to accommodate growing operations and better serve customer needs.
AIT-Johor Bahru | AIT-Kuala Lumpur | ||
No. 130 Jalan I-Park SAC 1/2 Taman Perindustrian I-Park 81400 Senai Johor Malaysia | 08-18 Kenwingston Business Centre Persiaran Bestari 63000 Cyberjaya Selangor Malaysia |
About AIT Worldwide Logistics
AIT Worldwide Logistics is a global freight forwarder that helps companies grow by expanding access to markets all over the world where they can sell and/or procure their raw materials, components and finished goods. For more than 40 years, the Chicago-based supply chain solutions leader has relied on a consultative approach to build a global network and trusted partnerships in nearly every industry, including aerospace, automotive, consumer retail, energy, food, government, high-tech, industrial, life sciences and marine. Backed by scalable, user-friendly technology, AIT’s flexible business model customizes end-to-end deliveries via sea, air, ground and rail — on time and on budget. With expert teammates staffing more than 150 worldwide locations in Asia, Europe and North America, AIT’s full-service options also include customs clearance, warehouse management and white glove services. Learn more at www.aitworldwide.com.
Our Mission
At AIT, we vigorously seek opportunities to earn our customers’ trust by delivering exceptional worldwide logistics solutions while passionately valuing our co-workers, partners and communities.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241112454642/en/
Contacts
Matt Sanders
Communications Director
+1 (630) 766-8300
msanders@aitworldwide.com
AIT Worldwide Logistics, Inc.
Global Headquarters
2 Pierce Place, Suite 2100
Itasca, IL 60143
800-669-4AIT (4248)
www.aitworldwide.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.aitworldwi
de.com%2F&esheet=54147462&newsitemid=20241112454642&lan=en-US&anchor=www.aitworl
dwide.com&index=2&md5=8a376de6e282f33ed59c177dbab3e228
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Nemluvio ® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis13.12.2024 23:09:00 CET | Press Release
Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies. This follows the recent U.S. FDA approval of Nemluvio for subcutaneous injection for the treatment of adults with prurigo nodularis in August 2024.12 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213562840/en/ Atopic dermatitis affects more than 230 million people worldwide, impacting approximately 7% of people in the U.S.2-4 Often reported as one of patients’ most problematic symptoms, 87% of people with atopic dermatitis say they are seeking freedom from itch, with speed of itch relief therefore also prioritized by both patient
Experian’s 2024 Global Identity & Fraud Report Spotlights Huge Growth in Highly Personalized GenAI-Driven Fraud Attacks13.12.2024 15:00:00 CET | Press Release
Today, Experian announced its 2024 Global Identity & Fraud Report that provides a comprehensive view of the consumer and business response to the latest fraud patterns and fraud‑mitigation strategies in the worldwide financial services sector. The report offers combined insights from more than 1,000 businesses and fraud leaders globally, as well as 4,000 consumers, focusing on fraud management and the digital experience. Among its key insights, the report casts a bright spotlight on three factors driving the fast-evolving fraud landscape: the huge growth in Generative Artificial Intelligence (GenAI) technologies, changing government regulations, and the push among businesses to provide consumers with secure and convenient digital experiences. In response to these factors, the report’s findings revealed that businesses intend to increase fraud budgets driven by investments in AI and machine learning technologies. “Unlike other issues facing financial services companies, fraud operates b
Capcom Announces Onimusha Way of the Sword , Marking the First New Title in the Series in Over 20 Years! Work on an Okami Sequel Project Begins!13.12.2024 14:00:00 CET | Press Release
Capcom Co., Ltd. (TOKYO:9697) today announced that Onimusha Way of the Sword, the first new title in the Onimusha series in over 20 years, is scheduled to be released, while work on an Okami sequel project has also started. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213232085/en/ Onimusha Way of the Sword (Graphic: Business Wire) The Onimusha series consists of swordplay action games where players assume the role of warriors with the superhuman powers of the Oni and fight against monsters bent on world domination. Onimusha Way of the Sword, scheduled to be released globally in 2026, is a Japanese-inspired dark fantasy game set at the beginning of the Edo period in Kyoto, which has been eerily transformed by clouds of Malice. In the game, the samurai protagonist is equipped with the Oni Gauntlet and engages in epic sword battles with the grotesque and otherworldly creatures known as Genma. Capcom hopes that players loo
BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell13.12.2024 13:51:00 CET | Press Release
BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and Cellistic, a leader in advanced iPS cell therapy manufacturing, today announced a process development and manufacturing agreement to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials. The strategic collaboration includes the use of Cellistic's innovative 3D bioreactor-based manufacturing platform, Echo, to enable GMP-compliant, clinical-scale manufacturing of iPSC-derived BCMA-targeting CAR-NKT cells for Phase 1 multiple myeloma trial; establishing BrightPath as a first mover in this emerging field. “The use of NKT cells as effectors in allogeneic CAR-T therapy represents a promising strategy, offering not only direct cytotoxicity but also indirect anti-tumor activity through the priming of host CD8+ T cells—a mechanism expected to evade host immune rejection and to enhance the dur
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union13.12.2024 07:00:00 CET | Press Release
Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the European Union (EU). The CHMP has recommended nemolizumab’s approval for subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy, and for subcutaneous use for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. This follows its approval for the treatment of adults with prurigo nodularis by the United States (U.S.) Food and Drug Administration (FDA) in August 2024.14 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212936857/en/ Atopic dermatitis is a common, chronic, and flaring infl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom